Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06161974 · ClinicalTrials.gov registry record · Phase 2
Study of Olutasidenib and Temozolomide in HGG
A Phase 2 study of High Grade Glioma and Diffuse Intrinsic Pontine Glioma, sponsored by Rigel Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 18
- Study locations
NCT06161974 is a Phase 2 study of High Grade Glioma and Diffuse Intrinsic Pontine Glioma that is actively recruiting participants, run by Rigel Pharmaceuticals. The registered enrollment target is 60 participants, roughly in line with the 64-participant average among 42 other High Grade Glioma trials with a reported enrollment target. The trial reports 18 study locations across 16 states.
The verdict
NCT06161974, a Phase 2 study of High Grade Glioma and Diffuse Intrinsic Pontine Glioma, is actively recruiting participants, sponsored by Rigel Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 18
- Study locations
Study Summary
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.
Conditions Studied
Interventions
- DRUG Olutasidenib + TMZ
Study Locations (18)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Nationwide Children's Hospital - Columbus
Other
- Princess Máxima Center - Utrecht
- Great Ormond Street Hospital - London
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Massachusetts
- Susan Chi - Boston
North Carolina
- Duke University Health System - Durham
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-03 |
| Est. Completion | 2035-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06161974
The ClinicalTrials.gov registry entry for NCT06161974 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 64-participant average among 42 other High Grade Glioma trials with a reported enrollment target. The listed sponsor is Rigel Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with High Grade Glioma appearing as the primary indexed condition, and to 1 intervention - of which Olutasidenib + TMZ is the first listed.
NCT06161974 reports 18 study locations spanning 16 distinct geographic areas - top geographies include Ohio, Other, Colorado.
Frequently Asked Questions
What is clinical trial NCT06161974 about?
NCT06161974 is a clinical study titled "Study of Olutasidenib and Temozolomide in HGG". The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozol...
What is the current status of trial NCT06161974?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-03. Estimated completion is 2035-06.
What conditions does trial NCT06161974 study?
This clinical trial studies the following conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Astrocytoma, Diffuse Midline Glioma, H3 K27M-Mutant, WHO Grade III Glioma.
What interventions are being tested in trial NCT06161974?
The interventions under investigation include: Olutasidenib + TMZ (DRUG).
Who is sponsoring clinical trial NCT06161974?
This trial is sponsored by Rigel Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06161974 being conducted?
This trial has 18 study locations across Colorado, District of Columbia, Illinois, Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
RECRUITING · Phase 2
-
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
RECRUITING · Phase 2
-
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
ACTIVE NOT RECRUITING · Phase 2
-
Low Dose Radiation Therapy for Glioblastoma Multiforme
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.